VTR(SZ:300381) Xin Lang Zheng Quan·2025-09-20 06:41Core Viewpoint - Guangdong Yidoli Biotechnology Co., Ltd. held an online investor meeting to discuss its mid-year performance and future strategies, focusing on product development and market expansion [1][2]. Group 1: Investor Relations Activity - The investor meeting took place on September 19, 2025, from 15:30 to 17:00 on the "Panorama Roadshow" website [2]. - Key personnel present included CEO Zhou Derong, independent director Yuan Ziqiang, CFO Huang Xiaoping, and board secretary Zhu Shanmin [2]. Group 2: Product Development and Market Strategy - The company has ceased production of Vitamin B12 due to market conditions and has made progress in animal plant extracts, completing various trials and obtaining new product certificates for red clover and stone mint extracts [2]. - In the human plant extract segment, the company developed multiple new products and optimized extraction processes, aiming for significant sales growth in overseas markets, with preparations for its German subsidiary completed [2]. Group 3: Production Capacity and Marketing - In 2024, the company produced 41,533 tons of biological enzyme preparations and sold 42,383 tons, achieving near full capacity utilization [2]. - The company is investing in new and upgraded projects across four bases to increase production capacity, while also expanding its global market presence by registering products in over 30 countries and establishing long-term partnerships with more than 2,300 quality clients [2]. Group 4: Shareholder Information and Market Management - As of September 10, 2025, the company had 20,222 shareholders [2]. - The management is focusing on core business development, research innovation, global market expansion, and efficiency improvements to achieve performance growth and high-quality development, alongside cash dividends, share buybacks, and equity incentives for market value management [2].